Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.59
VPHM's Cash to Debt is ranked higher than
60% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. VPHM: 1.59 )
VPHM' s 10-Year Cash to Debt Range
Min: 0.19   Max: No Debt
Current: 1.59

Equity to Asset 0.64
VPHM's Equity to Asset is ranked higher than
70% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. VPHM: 0.64 )
VPHM' s 10-Year Equity to Asset Range
Min: -0.32   Max: 0.96
Current: 0.64

-0.32
0.96
Interest Coverage 2.37
VPHM's Interest Coverage is ranked lower than
53% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. VPHM: 2.37 )
VPHM' s 10-Year Interest Coverage Range
Min: 2.37   Max: 9999.99
Current: 2.37

2.37
9999.99
F-Score: 2
Z-Score: 5.64
M-Score: -2.56
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) 7.79
VPHM's Operating margin (%) is ranked higher than
84% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. VPHM: 7.79 )
VPHM' s 10-Year Operating margin (%) Range
Min: -3900   Max: 66.57
Current: 7.79

-3900
66.57
Net-margin (%) 1.31
VPHM's Net-margin (%) is ranked higher than
80% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. VPHM: 1.31 )
VPHM' s 10-Year Net-margin (%) Range
Min: -3900   Max: 85.87
Current: 1.31

-3900
85.87
ROE (%) 0.74
VPHM's ROE (%) is ranked higher than
80% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. VPHM: 0.74 )
VPHM' s 10-Year ROE (%) Range
Min: -210.39   Max: 34.77
Current: 0.74

-210.39
34.77
ROA (%) 0.46
VPHM's ROA (%) is ranked higher than
81% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. VPHM: 0.46 )
VPHM' s 10-Year ROA (%) Range
Min: -111.39   Max: 26.11
Current: 0.46

-111.39
26.11
ROC (Joel Greenblatt) (%) 32.25
VPHM's ROC (Joel Greenblatt) (%) is ranked higher than
93% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. VPHM: 32.25 )
VPHM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -950.93   Max: 712.78
Current: 32.25

-950.93
712.78
Revenue Growth (%) 14.10
VPHM's Revenue Growth (%) is ranked higher than
86% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. VPHM: 14.10 )
VPHM' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 241
Current: 14.1

0
241
EBITDA Growth (%) 7.40
VPHM's EBITDA Growth (%) is ranked higher than
86% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. VPHM: 7.40 )
VPHM' s 10-Year EBITDA Growth (%) Range
Min: -54.2   Max: 39.9
Current: 7.4

-54.2
39.9
» VPHM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

VPHM Guru Trades in Q1 2013

Jim Simons 549,300 sh (New)
Steven Cohen 419,031 sh (+65.35%)
Manning & Napier Advisors, Inc 324,600 sh (+62.06%)
Murray Stahl 15,000 sh (unchged)
Pioneer Investments 376,430 sh (-2.48%)
Joel Greenblatt 183,556 sh (-19.32%)
» More
Q2 2013

VPHM Guru Trades in Q2 2013

Michael Price 85,000 sh (New)
George Soros 50,000 sh (New)
Manning & Napier Advisors, Inc 469,810 sh (+44.74%)
Murray Stahl 19,000 sh (+26.67%)
Pioneer Investments Sold Out
Jim Simons 97,000 sh (-82.34%)
Steven Cohen 67,200 sh (-83.96%)
Joel Greenblatt 6,987 sh (-96.19%)
» More
Q3 2013

VPHM Guru Trades in Q3 2013

Lee Ainslie 1,250,175 sh (New)
Michael Price 292,500 sh (+244.12%)
George Soros 100,000 sh (+100%)
Murray Stahl 19,000 sh (unchged)
Manning & Napier Advisors, Inc Sold Out
Jim Simons Sold Out
Joel Greenblatt Sold Out
Steven Cohen 11,297 sh (-83.19%)
» More
Q4 2013

VPHM Guru Trades in Q4 2013

Prem Watsa 10,000 sh (New)
Mario Gabelli 673,900 sh (New)
Jim Simons 630,800 sh (New)
John Paulson 1,300,000 sh (New)
Michael Price 400,000 sh (+36.75%)
Murray Stahl 19,000 sh (unchged)
George Soros Sold Out
Steven Cohen Sold Out
Lee Ainslie Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with VPHM

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2013-12-31 Add 36.75%0.7%$37.17 - $49.86 $ 49.9612%400000
Lee Ainslie 2013-12-31 Sold Out 0.66%$37.17 - $49.86 $ 49.9612%0
John Paulson 2013-12-31 New Buy0.32%$37.17 - $49.86 $ 49.9612%1300000
Mario Gabelli 2013-12-31 New Buy0.18%$37.17 - $49.86 $ 49.9612%673900
Prem Watsa 2013-12-31 New Buy0.04%$37.17 - $49.86 $ 49.9612%10000
George Soros 2013-12-31 Sold Out 0.04%$37.17 - $49.86 $ 49.9612%0
Michael Price 2013-09-30 Add 244.12%1.06%$29.24 - $40.78 $ 49.9653%292500
Lee Ainslie 2013-09-30 New Buy0.66%$29.24 - $40.78 $ 49.9653%1250175
George Soros 2013-09-30 Add 100%0.02%$29.24 - $40.78 $ 49.9653%100000
Joel Greenblatt 2013-09-30 Sold Out 0.01%$29.24 - $40.78 $ 49.9653%0
Michael Price 2013-06-30 New Buy0.33%$24.03 - $28.95 $ 49.9689%85000
Joel Greenblatt 2013-06-30 Reduce -96.19%0.22%$24.03 - $28.95 $ 49.9689%6987
George Soros 2013-06-30 New Buy0.02%$24.03 - $28.95 $ 49.9689%50000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about ViroPharma, Inc.

Mario Gabelli’s Top 5 Fourth-Quarter Stock Buys
Mario Gabelli (Trades, Portfolio)’s GAMCO Investors is in top form. The firm on Feb. 4 reported record assets under management at $47.0 billion, with a 93% increase in earnings per share and 24% increase in revenues in the fourth quarter compared to the previous year. Read more...

Ratios

vs
industry
vs
history
P/B 4.52
VPHM's P/B is ranked higher than
60% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. VPHM: 4.52 )
VPHM' s 10-Year P/B Range
Min: 0.44   Max: 13.99
Current: 4.52

0.44
13.99
P/S 8.02
VPHM's P/S is ranked higher than
58% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. VPHM: 8.02 )
VPHM' s 10-Year P/S Range
Min: 1.38   Max: 76.5
Current: 8.02

1.38
76.5
Shiller P/E 88.33
VPHM's Shiller P/E is ranked lower than
59% of the 175 Companies
in the Global Biotechnology industry.

( Industry Median: 38.74 vs. VPHM: 88.33 )
VPHM' s 10-Year Shiller P/E Range
Min: 9.22   Max: 89.04
Current: 88.33

9.22
89.04

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 23.20
VPHM's Price/Tangible Book is ranked lower than
85% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. VPHM: 23.20 )
VPHM' s 10-Year Price/Tangible Book Range
Min: 1.16   Max: 3400
Current: 23.2

1.16
3400
Price/DCF (Projected) 1.70
VPHM's Price/DCF (Projected) is ranked higher than
83% of the 210 Companies
in the Global Biotechnology industry.

( Industry Median: 2.80 vs. VPHM: 1.70 )
VPHM' s 10-Year Price/DCF (Projected) Range
Min: 0.32   Max: 78.36
Current: 1.7

0.32
78.36
Price/Median PS Value 1.90
VPHM's Price/Median PS Value is ranked lower than
59% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. VPHM: 1.90 )
VPHM' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 180.33
Current: 1.9

0.43
180.33
Earnings Yield (Greenblatt) 1.20
VPHM's Earnings Yield (Greenblatt) is ranked lower than
59% of the 378 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. VPHM: 1.20 )
VPHM' s 10-Year Earnings Yield (Greenblatt) Range
Min: 1.2   Max: 34.1
Current: 1.2

1.2
34.1
Forward Rate of Return (Yacktman) 2.39
VPHM's Forward Rate of Return (Yacktman) is ranked higher than
91% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. VPHM: 2.39 )
VPHM' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -137.8   Max: 45.5
Current: 2.39

-137.8
45.5

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:VPH.Germany
ViroPharma, Inc. was incorporated in Delaware in September 1994 and commenced operations in December 1994. It is a biotechnology company which develops and commercializes products that address serious diseases, used by physician specialists or in hospital settings. The Company's main development programs include C1 esterase inhibitor and a non-toxigenic strain of C. The Company markets and sells Cinryze in the United States for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema. Cinryze is a C1 esterase inhibitor therapy for routine prophylaxis against HAE, also known as C1 inhibitor deficiency, a rare, severely debilitating, life-threatening genetic disorder. Cinryze was obtained in October 2008, and On 8 January 2010, the company obtained expanded rights to commercialize Cinryze and future C1-INH derived products in certain European countries and other territories throughout the world as well as rights to develop future C1-INH derived products for additional indications. The Company also markets and sells Vancocin HCl capsules, the oral capsule formulation of vancomycin hydrochloride, in the U.S. and its territories. Vancocin is a potent antibiotic approved by the U.S. Food and Drug Administration, or FDA, to treat antibiotic-associated pseudomembranous colitis caused by Clostridium difficile infection, or C. difficile, and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. The Company's product development portfolio is consists of programs such as C1 esterase inhibitor [human], maribavir for cytomegalovirus infection, VP20621: prevention of recurrent CDAD and VP20629: treatment of Friedreich's Ataxia. The Company is working on developing further therapeutic uses; potential additional indications in other C1 mediated diseases, and alternative modes of administration for C1 esterase inhibitor. It is also developing VP20621 for the treatment and prevention of CDAD. On September 30, 2011, it entered into a license agreement for the worldwide rights of Intellect Neurosciences, Inc. to its clinical stage drug candidate, VP-20629, which is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against neurodegenerative disease. Its main competitors include both public and private entities, including well-known, large pharmaceutical companies, chemical companies, biotechnology companies and research institutions.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide